Literature DB >> 33411102

Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT.

Chao Ren1, Jingyun Ren1, Zhuang Tian2, Yanrong Du1, Zhixin Hao1, Zongyao Zhang3, Wei Fang3, Fang Li1, Shuyang Zhang2, Bailing Hsu4, Li Huo5.   

Abstract

BACKGROUND: 99mTc-PYP scintigraphy provides differential diagnosis of ATTR cardiomyopathy (ATTR-CM) from light chain cardiac amyloidosis and other myocardial disorders without biopsy. This study was aimed to assess the diagnostic feasibility and the operator reproducibility of 99mTc-PYP quantitative SPECT.
METHOD: Thirty-seven consecutive patients who underwent a 99mTc-PYP thorax planar scan followed by SPECT and CT scans to diagnose suspected ATTR-CM were enrolled. For the quantitative SPECT, phantom studies were initially performed to determine the image conversion factor (ICF) and partial volume correction (PVC) factor to recover 99mTc-PYP activity concentration in the myocardium for calculating the standardized uptake value (SUV) (unit: g/ml). SUVmax was compared among groups of ATTR-CM, AL cardiac amyloidosis, and other pathogens (others) and among categories of Perugini visual scores (grades 0-3). The intra- and inter-operator reproducibility of quantitative SPECT was verified, and the corresponded repeatability coefficient (RPC) was calculated.
RESULTS: The ICF was 79,327 Bq/ml to convert count rate in pixel to 99mTc activity concentration. PVC factor as a function of the measured activity concentration ratio in the myocardium and blood-pool was [y = 1.424 × (1 - exp(- 0.759 × x)) + 0.104]. SUVmax of ATTR-CM (7.50 ± 2.68) was significantly higher than those of AL (1.96 ± 0.35) and others (2.00 ± 0.74) (all p < 0.05). SUVmax of grade 3 (8.95 ± 1.89) and grade 2 (4.71 ± 0.23) were also significantly higher than those of grade 1 (1.92 ± 0.31) and grade 0 (1.59 ± 0.39) (all p < 0.05). Correlation coefficient (R2) of SUVmax reached 0.966 to 0.978 with only small systematic difference (intra = - 0.14; inter = - 0.23) between two repeated measurements. Intra- and inter-operator RPCs were 0.688 and 0.877.
CONCLUSIONS: 99mTc-PYP quantitative SPECT integrated with adjustable PVC factors is feasible to quantitatively and objectively assess the burden of cardiac amyloidosis for diagnosis of ATTR-CM.

Entities:  

Keywords:  99mTc-PYP quantitative SPECT; ATTR cardiomyopathy; Diagnostic feasibility; Standardized uptake value; The operator reproducibility

Year:  2021        PMID: 33411102     DOI: 10.1186/s40658-020-00342-7

Source DB:  PubMed          Journal:  EJNMMI Phys        ISSN: 2197-7364


  22 in total

Review 1.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

Review 2.  Myocardial Amyloidosis: The Exemplar Interstitial Disease.

Authors:  Marianna Fontana; Andrej Ćorović; Paul Scully; James C Moon
Journal:  JACC Cardiovasc Imaging       Date:  2019-08-14

3.  Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans.

Authors:  Daniel R Jacobson; Alice A Alexander; Clement Tagoe; Joel N Buxbaum
Journal:  Amyloid       Date:  2015-07-02       Impact factor: 7.141

4.  Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.

Authors:  Maarit Tanskanen; Terhi Peuralinna; Tuomo Polvikoski; Irma-Leena Notkola; Raimo Sulkava; John Hardy; Andrew Singleton; Sari Kiuru-Enari; Anders Paetau; Pentti J Tienari; Liisa Myllykangas
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

5.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983

Review 6.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

7.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).

Authors:  Mathew S Maurer; Mazen Hanna; Martha Grogan; Angela Dispenzieri; Ronald Witteles; Brian Drachman; Daniel P Judge; Daniel J Lenihan; Stephen S Gottlieb; Sanjiv J Shah; D Eric Steidley; Hector Ventura; Srinivas Murali; Marc A Silver; Daniel Jacoby; Savitri Fedson; Scott L Hummel; Arnt V Kristen; Thibaud Damy; Violaine Planté-Bordeneuve; Teresa Coelho; Rajiv Mundayat; Ole B Suhr; Márcia Waddington Cruz; Claudio Rapezzi
Journal:  J Am Coll Cardiol       Date:  2016-07-12       Impact factor: 24.094

8.  [The diagnostic and prognostic values of serum free light chain in patients with primary light chain amyloidosis].

Authors:  C L Zhang; J Feng; K N Shen; W Su; C L Zhang; X F Huang; X X Cao; L Zhang; D B Zhou; J Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-11-14

9.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

Authors:  Adam Castaño; David L Narotsky; Nadira Hamid; Omar K Khalique; Rachelle Morgenstern; Albert DeLuca; Jonah Rubin; Codruta Chiuzan; Tamim Nazif; Torsten Vahl; Isaac George; Susheel Kodali; Martin B Leon; Rebecca Hahn; Sabahat Bokhari; Mathew S Maurer
Journal:  Eur Heart J       Date:  2017-10-07       Impact factor: 29.983

10.  Systemic amyloidosis in England: an epidemiological study.

Authors:  Jennifer H Pinney; Colette J Smith; Jessi B Taube; Helen J Lachmann; Christopher P Venner; Simon D J Gibbs; Jason Dungu; Sanjay M Banypersad; Ashutosh D Wechalekar; Carol J Whelan; Philip N Hawkins; Julian D Gillmore
Journal:  Br J Haematol       Date:  2013-03-11       Impact factor: 6.998

View more
  6 in total

Review 1.  2021 Advocacy Statements for the Role of 99mTc-Pyrophosphate Scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis: A Report of the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.

Authors:  Yih-Hwen Huang; Yen-Hung Lin; Ruoh-Fang Yen; Charles Jia-Yin Hou; Shan-Ying Wang; Shih-Chuan Tsai; Kung-Chu Ho; Ming-Hsien Lin; Chin-Ho Tsao; Chih-Yung Chang; Jin-Long Huang; Mei-Fang Cheng; Yen-Wen Wu
Journal:  Acta Cardiol Sin       Date:  2021-05       Impact factor: 2.672

2.  Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications.

Authors:  Robert J H Miller; Nowell Fine
Journal:  J Nucl Cardiol       Date:  2021-12-17       Impact factor: 5.952

3.  Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.

Authors:  Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu
Journal:  J Nucl Cardiol       Date:  2022-07-21       Impact factor: 3.872

4.  Usefulness of quantitative 99mTc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis.

Authors:  Kouji Ogasawara; Shinya Shiraishi; Noriko Tsuda; Fumi Sakamoto; Seitarou Oda; Seiji Takashio; Kenichi Tsujita; Toshinori Hirai
Journal:  Jpn J Radiol       Date:  2022-01-01       Impact factor: 2.374

5.  Reliability and feasibility of visual grading systems and quantitative indexes on [99mTc]Tc-DPD imaging for cardiac amyloidosis.

Authors:  Sungwoo Bae; Joonhyung Gil; Jin Chul Paeng; Eun-Ah Park; Seung-Pyo Lee; Hongyoon Choi; Keon Wook Kang; Gi Jeong Cheon; Dong Soo Lee
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

6.  Pitfalls of the Semi-Quantitative Analyzing 99mTc-Pyrophosphate Planar Images for Diagnosing Transthyretin Cardiac Amyloidosis: A Possible Solution.

Authors:  Yuankai Zhu; Ruping Pan; Dan Peng; Qingjian Dong; Xiaohua Zhu
Journal:  Diagnostics (Basel)       Date:  2022-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.